OBJECTIVES
Deep learning neural network (DLNN)-based tools can automate body composition analysis for cancer cachexia research. We aimed to evaluate a DLNN tool trained on a European population of Chinese cancer patients.
METHODS
Computed tomography (CT) images at the 3rd lumbar vertebral (L3)...
Cancer cachexia, which is characterized by weight loss and muscle wasting with or without fat depletion, is a complex syndrome that commonly seen in patients with advanced cancer. The underlying pathophysiological mechanisms of cancer cachexia involve in systemic inflammation, abnormal...
BACKGROUND
Reduced muscle mass and impaired composition have each been independently associated with worse outcomes in patients with cancer. However, emerging evidence suggests that reduced muscle strength-namely, dynapenia-may be particularly important for prognostication, as it is easier to assess in clinical...
Sarcopenia is an age-related condition characterized by loss of skeletal muscle mass and strength and is associated with increased cancer incidence and mortality, yet how muscle decline promotes tumorigenesis remains unclear. Here, we show that skeletal muscle functions as an...
BACKGROUND
New-onset sarcopenia may develop after gastrectomy even in patients with normal muscle mass, but its detection in routine practice remains challenging. This study evaluated body composition changes after gastrectomy and identified clinical parameters associated with sarcopenia development.
METHODS
This retrospective study included...
BACKGROUND
Cancer cachexia is a debilitating syndrome characterized by severe skeletal muscle wasting, which significantly impairs patient quality of life and survival. Indoleamine 2,3-dioxygenase 1 (IDO1), a key enzyme in tryptophan (Trp) metabolism, is often upregulated in cancers, but its specific...
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural...
Cancer cachexia is a systemic metabolic syndrome driven by tumor-induced disruption of whole-body homeostasis. Characterized by skeletal muscle atrophy and adipose tissue loss, cachexia leads to functional decline, impaired quality of life, reduced treatment tolerance, and poor survival across multiple...
Radiotherapy, while a cornerstone treatment for esophageal squamous cell carcinoma (ESCC), is paradoxically associated with significant weight loss that portends poor patient outcomes. The mechanisms driving this metabolic complication remain elusive. Here, we identified adipose depletion - rather than muscle...
BACKGROUND
Unintentional weight loss (UWL) is the primary diagnostic parameter for cancer cachexia in the clinic. Prompt identification of UWL can lead to earlier diagnoses and interventions for cancer. This study investigates the frequency and timing of UWL documentation and diagnoses...
INTRODUCTION
Changes in body composition (BC) are associated with outcomes in colorectal cancer (CRC), with adverse features such as sarcopenia, myosteatosis, and excess adiposity linked to the systemic inflammatory response (SIR). Whilst ethnic differences in BC have been identified in healthy...
ObjectivesWe investigated the associations of nutrition impact symptoms (NISs) with sleep disturbance among advanced cancer patients receiving palliative care.MethodsA secondary analysis of a self-administered survey was performed. Participants evaluated 3 components of sleep disturbance (ie, difficulty falling asleep, difficulty staying...
Cancer cachexia, characterized by severe body weight loss, negatively affects patient quality of life and survival. Although moderate exercise benefits healthy and chronically ill individuals, and the effect of exercise in cachexia generally appears beneficial, conflicting results have been reported...
BACKGROUND
Cachexia is a debilitating syndrome associated with involuntary weight loss, often occurring in cancer patients. In both humans and animal models, alterations in endocannabinoid (eCB) signaling occur in association with both metabolic disorders and several types of tumors. The wider...
